FDA Classifies Special Baby Sleep System as Class II
Published Date: 6/26/2026
Rule
Summary
The FDA has officially placed the infant supine sleep system into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps make sure the device is safe and effective while making it easier for companies to bring these helpful baby sleep products to market. The new classification took effect on June 26, 2026, but has been in place since March 30, 2023, so manufacturers and parents can breathe easy!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Infant sleep system reclassified to Class II
The FDA has classified the infant supine sleep system as Class II (special controls). This classification is codified at 21 CFR 880.5690, became applicable on March 30, 2023, and the final order is effective June 26, 2026.
510(k) premarket notification still required
Infant supine sleep systems are subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless FDA grants an exemption under section 510(m). This classification remained applicable on March 30, 2023 and the final order is effective June 26, 2026.
New testing, data, and warning label rules
The special controls require clinical data and postmarket surveillance, human factors testing, biocompatibility, non-clinical performance testing (including tipping and cleaning compatibility), and specific labeling. Labeling must include a prominent warning that the device has not been demonstrated to reduce SIDS/SUID and must provide instructions for fit, cleaning, and safe sleep practices.
De Novo classification creates predicate for future devices
Because the device was classified via the De Novo process, the infant supine sleep system can serve as a predicate device for future substantially equivalent devices, allowing future sponsors to use the less burdensome 510(k) pathway rather than De Novo or premarket approval.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12953 — Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Previous / Next Documents
Previous: 2026-12904 — Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome
The FDA has officially placed the external lower leg nerve stimulator for Restless Legs Syndrome into a safer, easier-to-get category called Class II. This change helps patients get access to this helpful device faster while keeping safety in check. The new rules took effect on June 26, 2026, and could lower costs by cutting some red tape for makers and users alike.
Next: 2026-12913 — Cinnamaldehyde in Pesticide Formulations; Exemption From the Requirement for a Tolerance
The EPA just made life easier for farmers and pesticide makers by saying cinnamaldehyde (a cinnamon-smelling ingredient) doesn’t need a strict residue limit when used in pesticides—up to 100 parts per million. This rule kicks in on June 26, 2026, saving time and money by cutting red tape. If anyone wants to object, they have until August 25, 2026, to speak up.